Karimi Mehdi, Shirsalimi Niyousha, Sedighi Eshagh
Faculty of Medicine, Bogomolets National Medical University (NMU), Kyiv, Ukraine.
Faculty of Medicine, Hamadan University of Medical Science (UMSHA), Hamadan, Iran.
Int J Emerg Med. 2024 Dec 19;17(1):190. doi: 10.1186/s12245-024-00774-3.
Thromboembolic disorders, including deep vein thrombosis (DVT) and pulmonary embolism (PE), are major global health concerns, causing significant morbidity and mortality. Early diagnosis is crucial for effective treatment and improved patient outcomes. Recent research has identified Apelin-13, a bioactive peptide in the apelin family, as a promising diagnostic biomarker for Thromboembolic disorders. Apelin-13 supports vascular health by regulating protease balance through plasminogen activator inhibitors and modulating endothelial cell function. Additionally, it plays a vital role in coagulation, with elevated levels associated with an increased risk of clot formation, suggesting its utility in predicting thrombosis risk, particularly in preoperative evaluations. Findings indicate that the Apelin-13 pathway shows significant promise as a biomarker for Thromboembolic disorders, underscoring its potential therapeutic applications and the need for further investigation. This review synthesizes current literature on thromboembolic disorders and associated laboratory biomarkers, with a particular focus on Apelin-13. It examines Apelin-13's role in disease mechanisms, its physiological functions, and its potential as a diagnostic biomarker in thromboembolic conditions.
血栓栓塞性疾病，包括深静脉血栓形成（DVT）和肺栓塞（PE），是全球主要的健康问题，会导致严重的发病率和死亡率。早期诊断对于有效治疗和改善患者预后至关重要。最近的研究已确定Apelin-13（一种apelin家族中的生物活性肽）是血栓栓塞性疾病有前景的诊断生物标志物。Apelin-13通过纤溶酶原激活物抑制剂调节蛋白酶平衡和调节内皮细胞功能来支持血管健康。此外，它在凝血过程中起重要作用，其水平升高与血栓形成风险增加相关，表明其在预测血栓形成风险方面的效用，特别是在术前评估中。研究结果表明，Apelin-13途径作为血栓栓塞性疾病的生物标志物显示出巨大前景，强调了其潜在的治疗应用以及进一步研究的必要性。本综述综合了关于血栓栓塞性疾病和相关实验室生物标志物的当前文献，特别关注Apelin-13。它研究了Apelin-13在疾病机制中的作用、其生理功能以及其作为血栓栓塞性疾病诊断生物标志物的潜力。
